RxDoctor Payments Data

Molly Boge, PA

Medical · Dubuque, IANPI 1568099117

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.7% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Teleflex LLC at 38.3% of the total. Reporting peaked in 2023 at $539 and has fallen 82.2% since, to $96 in 2025.

$1,556in general payments, 2019–2025

Across 52 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$596
  • Medtronic$219
  • AbbVie$196
  • Astellas Pharma US Inc$162
  • 180 Medical, Inc.$124
  • Axonics, Inc.$106
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$1,50497%
  • Education$523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,556 in reported general payments places this provider in the 75th percentile of 141 medical providers in Iowa.

See all medical providers in Iowa

Medicare billing

Part B allowed, 2024
$48,935
Medicare patients
274
Services billed
3,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron76$46,999
MyrbetriqMirabegron75$32,341
Solifenacin Succinate147$4,936
Estradiol39$3,741
Oxybutynin Chloride ErOxybutynin Chloride143$3,446
Tamsulosin Hcl271$3,232
Methenamine Hippurate59$2,749
Fesoterodine Fumarate ErFesoterodine Fumarate35$2,388
Finasteride140$1,021
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$835
Cephalexin135$800
Cefdinir27$787
Oxybutynin Chloride86$782
NitrofurantoinNitrofurantoin Macrocrystal21$619
Tolterodine Tartrate ErTolterodine Tartrate12$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$16$46,99976 claims
Astellas Pharma US IncMyrbetriq$162$32,34175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 141 medical providers in Iowa.

Other medical in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →